Welcome to our dedicated page for Biofrontera news (Ticker: BFRI), a resource for investors and traders seeking the latest updates and insights on Biofrontera stock.
Biofrontera Inc. (NASDAQ: BFRI) is a U.S.-based biopharmaceutical company specializing in dermatology and photodynamic therapy (PDT). Its news flow centers on the commercialization and clinical development of Ameluz® and the RhodoLED® lamp series for the treatment of actinic keratoses and other skin conditions.
On this page, readers can follow company announcements related to financial results, such as quarterly and annual revenue updates, as well as business updates describing trends in Ameluz® sales and operating expenses. Biofrontera frequently reports on revenue performance, gross margin developments, and the impact of its strategic agreements on its financial profile.
News items also highlight clinical and regulatory milestones. These include database locks and completion of clinical studies in actinic keratosis on peripheral body areas, Phase 1 pharmacokinetics data, Phase 3 results in superficial basal cell carcinoma, and Phase 2 progress in acne vulgaris. The company uses press releases to describe how these data support supplemental New Drug Applications and future Phase 3 programs.
In addition, Biofrontera issues updates on strategic transactions and capital markets activity, such as the acquisition of all U.S. rights to Ameluz® and RhodoLED® from Biofrontera AG, changes to royalty and earnout structures, private placements of convertible preferred stock, and the divestiture of its Xepi® antibiotic cream license. Regulatory notices regarding Nasdaq listing compliance and participation in investor conferences are also part of the company’s regular news flow.
Investors and observers who want to track developments in dermatologic photodynamic therapy, label expansion efforts for Ameluz®-PDT, and Biofrontera’s financial and strategic progress can use this news feed as a centralized source of company-issued updates.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.